Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | ESR1 | P03372 | 2/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Nitroaniline SCHEMBL16451 | 0.95 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1MAPTESR1 | |
| 4-Nitroaniline SCHEMBL13529022 | 0.95 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1MAPTESR1 | |
| SCHEMBL9065915 | 0.95 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1MAPTESR1 | |
| 4-Nitroaniline SCHEMBL27963818 | 0.95 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1MAPTESR1 | |
| 4-Nitroaniline SCHEMBL28869855 | 0.93 | ALDH1A1 (0.86) | ALDH1A1KMT2AMEN1MAPTESR1 | |
| 4-Nitroaniline SCHEMBL11498181 | 0.92 | ALDH1A1 (0.95) | ALDH1A1KMT2AMEN1MAPTESR1 | |
| 4-Nitroaniline SCHEMBL7158084 | 0.92 | ALDH1A1 (0.95) | ALDH1A1KMT2AMEN1MAPTESR1 | |
| 4-Nitroaniline SCHEMBL356765 | 0.92 | ALDH1A1 (0.95) | ALDH1A1KMT2AMEN1MAPTESR1 | |
| 4-Nitroaniline SCHEMBL21825602 | 0.92 | ALDH1A1 (0.95) | ALDH1A1KMT2AMEN1MAPTESR1 | |
| 4-Nitroaniline SCHEMBL6956705 | 0.92 | ALDH1A1 (0.95) | ALDH1A1KMT2AMEN1MAPTESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765053-B2 | Methods of treatment using selective 5-HT2A inverse agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2017-06-15 | — | — | US | disclosed |
| EP-1787984-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARM INC (US) | 2016-08-18 | — | — | US | disclosed |
| US-9296694-B2 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150259291-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARMACEUTICALS INC. | 2015-09-17 | — | — | US | disclosed |
| CN-1443167-B | Azacyclo compounds for the treatment of 5-hydroxytryptamine related disorders | ACADIA PHARM INC | 2012-07-18 | — | — | CN | disclosed |
| US-20110301191-A1 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2011-12-08 | — | — | US | disclosed |
| US-20090186921-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| CN-101230034-A | Nitrogen hetero-cycle compounds for use in the treatment of 5-hydroxide tryptamines related diseases | ACADIA PHARM INC (US) | 2008-07-30 | — | — | CN | disclosed |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060194834-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | disclosed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | disclosed |
| US-6756393-B2 | AMIDES AND UREAS N-SUBSTITUTED WITH PIPERIDINE OR NORTROPANE; SEROTONIN INVERSE AGONISTS OR ANTAGONISTS; ANTIPSYCHOTIC | ACADIA PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | disclosed |
| CN-1443167-A | Azacyclo compounds for the treatment of 5-hydroxytryptamine related disorders | ACADIA PHARM INC (US) | 2003-09-17 | — | — | CN | disclosed |
| EP-1263729-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Acadia Pharmaceuticals Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | disclosed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259291-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | ALDH1A1 1093/4885KMT2A 958/4885MEN1 570/4885 |
| US-20110301191-A1 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | ALDH1A1 2458/4885KMT2A 1969/4885MEN1 1617/4885 |
| US-20060194834-A1 | Azacyclic compounds | HTR6, HTR5A, HNMT | ALDH1A1 1235/4885KMT2A 1270/4885MEN1 710/4885 |
| US-20090186921-A1 | AZACYCLIC COMPOUNDS | HTR6, HTR5A, HNMT | ALDH1A1 1235/4885KMT2A 1270/4885MEN1 710/4885 |
| US-20030220316-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | ALDH1A1 1093/4885KMT2A 958/4885MEN1 570/4885 |
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | ALDH1A1 1093/4885KMT2A 958/4885MEN1 570/4885 |
| US-20050014757-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | ALDH1A1 1093/4885KMT2A 958/4885MEN1 570/4885 |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | ALDH1A1 2458/4885KMT2A 1969/4885MEN1 1617/4885 |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | ALDH1A1 1093/4885KMT2A 958/4885MEN1 570/4885 |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | HTR2A, HTR1A, HTR1B | ALDH1A1 2975/4885KMT2A 1361/4885MEN1 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.